When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy

dc.contributor.author	Avogaro, Angelo
dc.contributor.author	Delgado Álvarez, Elías
dc.contributor.author	Lingvay, Ildiko
dc.date.accessioned	2018-10-08T10:23:03Z
dc.date.available	2018-10-08T10:23:03Z
dc.date.issued	2018
dc.identifier.citation	Diabetes/Metabolism Research and Reviews, 34(4), p. e2981- (2018); doi:10.1002/dmrr.2981
dc.identifier.issn	1520-7552
dc.identifier.uri	http://hdl.handle.net/10651/48712
dc.format.extent	p. e2981-
dc.language.iso	eng
dc.relation.ispartof	Diabetes/Metabolism Research and Reviews, 34
dc.rights	© 2018 John Wiley & Sons, Ltd.
dc.source	Scopus
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046355801&doi=10.1002%2fdmrr.2981&partnerID=40&md5=6ec7f46096f89fae14707833bbf927d9
dc.title	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy
dc.type	journal article
dc.identifier.doi	10.1002/dmrr.2981
dc.relation.publisherversion	http://dx.doi.org/10.1002/dmrr.2981

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.